Jennifer Pietenpol Archives
VICC Scientific Retreat focuses on lung cancer
May. 5, 2022—by Tom Wilemon Speakers at the Vanderbilt-Ingram Cancer Center (VICC) 23rd Annual Scientific Retreat celebrated “Advances in Lung Cancer Research” but noted that too many people with the disease are not benefiting from those achievements. “Lung cancer is our leading cause of cancer mortality. Twenty-nine percent of our total cancers are lung cancer. That’s the...
VUMC’s Pietenpol, Shyr named AACR Fellows
Mar. 22, 2022—Vanderbilt's Jennifer Pietenpol, PhD, and Yu Shyr, PhD, have been inducted as fellows of the American Association for Cancer Research Academy.
Pietenpol named chief scientific and strategy officer
Feb. 10, 2022—Jennifer Pietenpol, PhD, director of the Vanderbilt-Ingram Cancer Center (VICC), Benjamin F. Byrd Jr. Professor of Oncology and Executive Vice President for Research for Vanderbilt University Medical Center, is stepping down on June 30 from her long-held role as the Cancer Center’s director to focus on a combined leadership role for VUMC as chief scientific and strategy officer (CSSO).
‘Multi-omics’ reveals treatment option for breast cancer subtype
Nov. 18, 2021— by Bill Snyder In a multidisciplinary collaboration, researchers at Vanderbilt University Medical Center and the University of Miami Miller School of Medicine have identified a subtype of triple-negative breast cancer (TNBC) that appears to be able to escape detection by the immune system and evade immunotherapy. Their report, published Nov. 1 in the journal...
Discovery offers insight for development of cancer therapies targeting mutant p53
Sep. 2, 2021—Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.
Expression atlas for cell regulators
Aug. 19, 2021—Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.
Susan G. Komen funds VICC breast cancer initiatives
Jul. 15, 2021—Susan G. Komen has announced breast cancer research grants totaling $14 million, including funding for three separate initiatives led by Vanderbilt-Ingram Cancer Center (VICC) researchers.
VICC receives ‘exceptional’ score with renewal as an NCI-Designated Comprehensive Cancer Center
Sep. 29, 2020—Vanderbilt-Ingram Cancer Center (VICC) received an overall “exceptional” score for its research impact and excellence in patient care. This achievement merits renewed funding from the National Cancer Institute (NCI) and places it once again in a top group of NCI Comprehensive Cancer Centers.
Vanderbilt-Ingram opens cancer center in Wilson County
Aug. 27, 2020—Vanderbilt-Ingram Cancer Center at Wilson County is slated to open Aug. 31 with a full array of highly specialized services, including diagnostic assessments, medical oncology and radiation oncology.
New space bolsters infectious disease and immunology discovery
Jul. 9, 2020—The Vanderbilt Institute for Infection, Immunology and Inflammation (VI4) recently moved into its new research and administrative home.
State cancer plan has robust input and commitment from Vanderbilt-Ingram Cancer Center
May. 21, 2020—More than a dozen representatives of Vanderbilt University Medical Center helped plan and made a commitment to help carry out the strategy for how Tennessee will prevent cancer and minimize its burden on state residents.
VUMC research ramps up in COVID-19 transition
May. 21, 2020—As Nashville cautiously begins to emerge from its two-month-long COVID-19 Safer at Home response, so too are the labs and facilities at Vanderbilt University Medical Center.
